Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Alphabet, Wells Fargo, PetroChina, Micron and Allstate

Read MoreHide Full Article

For Immediate Release

Chicago, IL – March 25, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet (GOOGL - Free Report) , Wells Fargo (WFC - Free Report) , PetroChina (PTR - Free Report) , Micron (MU - Free Report) and Allstate (ALL - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Analyst Reports for Alphabet, Wells Fargo and PetroChina

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet, Wells Fargo and PetroChina. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Alphabet's shares have outperformed the Zacks Internet Services industry in the past year (+20.4% vs. -4.6%).The Zacks analyst thinks Alphabet is riding on its growing search initiatives. Its strong initiatives toward elimination of bad ads and introducing useful major search updates are acting as tailwinds. These are enhancing its search results.

Further, Google’s robust mobile search is also a major positive. Additionally, its strong focus toward bolstering presence in the cloud market on the back of expanding data centers and robust cloud offerings continues to aid top-line growth.

The company’s strong focus on innovation related to its AI techniques and Android OS along with growing presence in the home automation space are aiding business growth further. However, the company’s growing litigation issues might hurt its profitability. Also, it's increased spending on consumer gadgets, YouTube video app and cloud computing services remains a concern.

Shares of Wells Fargo have underperformed the Zacks Major Regional Banks industry over the past three months (up +14.4% vs. +17.4%).Its earnings surprise history is decent, having beaten expectations in two of the trailing four quarters. The Zacks analyst likes the ongoing investments in the businesses to enhance compliance and risk management capability, build a better bank and strengthen core infrastructure.

The bank settled fake account scandal-related lawsuit filed by shareholders and ended investigations by about 50 states, which will enable it to focus on operations. However, Wells Fargo was slapped with several sanctions, including a cap on its assets by the Federal Reserve, following its involvement in several legal issues. Its reputation was harmed by such involvement and might take some time to recover. Falling mortgage banking income is another concern.

PetroChina’s shares have gained +11.2% year to date, underperforming the Zacks International Integrated Oil industry, which has increased +13.6% over the same period. The Zacks analyst thinks that since higher oil prices will likely support the state-run giant's upstream unit in the near-to-medium term, the stock might regain favor.

The company's exploration & production segment has been benefiting from steady commodity price recovery and stricter cost control. Meanwhile, the downstream business -- consisting of the refining and chemicals’ activities – should be able to take advantage of optimized resource allocation, strict cost control and increased production of high-value products.

However, the company's weak oil production growth prospects are a major concern. Limited international operations and losses on gas imports give investors more reason to be cautious about the stock.

Other noteworthy reports we are featuring today include Micron and Allstate.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

http://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like